By Adria Calatayud
Roche Holding said a drug combination including a new experimental breast-cancer treatment fell short of its primary objective in a late-stage clinical trial.
The Swiss pharmaceutical company said Monday that the combination of its investigational drug, giredestrant, with Pfizer's Ibrance didn't meet the primary objective of a statistically significant improvement in progression-free survival in patients with advanced breast cancer.
The company said a numerical improvement in progression-free survival was observed in the trial and that the drug combination was well tolerated, with adverse events consistent with the known safety profiles of each treatment.
This was the first of two late-stage studies for giredestrant as a first-line treatment, Roche said. Results of the other study are due to be published next year, it said.
Roche's chief medical officer and head of global product development, Levi Garraway, said the company sees a path forward for combining giredestrant with another drug, such as in the adjuvant setting when patients have already received an initial cancer treatment.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
03-09-26 0240ET
